Daniel Robinson

This inventor holds 20 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 11 EPO patents, primarily in Kinase Inhibitors. Top assignee: Vertex Pharmaceuticals, Inc.. Active years: 2009-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Robinson. Retrieved from https://idiyas.com/inventor/daniel-robinson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 8)

% Patents Active = 30.0

CIPO Patents = 1

EPO Patents = 11 (Patent Applications = 7)

Average Co-Inventor Count = 6.2

ph-index = 14

Forward Citations = 397(Granted Patents)

Location History:

Oxfordshire, GB (2009 - 2010)
Abingdon, GB (2009 - 2015)

Company Filing History:

20 out of 1,168

Vertex Pharmaceuticals, Inc.

patents

Years Active: 2009-2015

Loading Chart...

Areas of Expertise:

Kinase Inhibitors

Azaindoles

Thiazoles

Imidazoles

Pyrazoles

Aminopyrimidines

Pyrrolopyrazines

Benzimidazoles

Protein Kinases

Compositions

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8987454 - Azaindoles useful as inhibitors of JAK and other protein kinases (2015-03-24),

2. 8865751 - Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases (2014-10-21),

3. 8785444 - Thiazoles and pyrazoles useful as kinase inhibitors (2014-07-22),

4. 8722889 - Azaindoles useful as inhibitors of JAK and other protein kinases (2014-05-13),

5. 8642779 - Compositions useful as inhibitors of protein kinases (2014-02-04),

6. 8637511 - Aminopyrimidines useful as kinase inhibitors (2014-01-28),

7. 8501446 - Azaindoles useful as inhibitors of JAK and other protein kinases (2013-08-06),

8. 8383633 - Aminopyrimidines useful as kinase inhibitors (2013-02-26),

9. 8372835 - Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases (2013-02-12),

10. 8268811 - Thiazoles and pyrazoles useful as kinase inhibitors (2012-09-18),

11. 8236832 - Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases (2012-08-07),

12. 8188281 - Azaindoles useful as inhibitors of JAK and other protein kinases (2012-05-29),

13. 8129399 - Aminopyrimidines useful as kinase inhibitors (2012-03-06),

14. 8076343 - Benzimidazoles useful as inhibitors of protein kinases (2011-12-13),

15. 7795259 - Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases (2010-09-14),

Title: Inventor Spotlight: Daniel Robinson, Pushing Boundaries in Pharmaceutical Innovation

Introduction: Meet Daniel Robinson, a prolific inventor hailing from Abingdon, GB, whose drive for innovation has resulted in an impressive portfolio of 20 patents.

Latest Patents: Daniel's latest patents focus on groundbreaking research in the field of pharmaceuticals. His inventions include "Azaindoles useful as inhibitors of JAK and other protein kinases", showcasing his expertise in developing inhibitors for protein kinases. Additionally, Daniel's patent on "Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases" demonstrates his commitment to advancing treatments for various diseases and conditions.

Career Highlights: Currently employed at Vertex Pharmaceuticals, Inc., Daniel Robinson contributes his inventive prowess to a renowned pharmaceutical company. His dedication to research and development has led to significant advancements in drug therapies, benefiting patients worldwide.

Collaborations: In his professional journey, Daniel has collaborated closely with esteemed colleagues such as Michael P Mortimore and Simon Everitt. Together, they have synergized their skills and expertise to drive innovation and excellence in the pharmaceutical industry.

Conclusion: In conclusion, Daniel Robinson stands out as a leading figure in the world of pharmaceutical innovation, with a remarkable track record of patenting novel compounds for the treatment of diverse health conditions. His relentless pursuit of scientific discovery continues to inspire and shape the future of medicine.

Profile summary based on public USPTO records.